Tesamorelin (5MG / 10MG)

What Is Tesamorelin?

Tesamorelin is a synthetic 44-amino acid peptide corresponding to the full-length sequence of endogenous human growth hormone-releasing hormone (GHRH(1-44)). For researchers looking to buy Tesamorelin in Switzerland for growth hormone and metabolic research, this peptide offers a stabilized analog of the endogenous hypothalamic peptide with enhanced pharmacokinetic properties.

Native GHRH is a 44-amino acid hypothalamic peptide that acts on the anterior pituitary to stimulate the synthesis and pulsatile release of endogenous growth hormone (GH). However, endogenous GHRH has a plasma half-life of only a few minutes due to rapid enzymatic degradation by dipeptidyl peptidase IV (DPP-IV), which cleaves the first two residues upon contact. Tesamorelin incorporates a critical structural modification: a trans-3-hexenoic acid group (a short unsaturated fatty acid) attached to the N-terminus. This hexenoyl cap shields the peptide from rapid enzymatic degradation, roughly tripling its plasma persistence without altering its receptor binding profile. The peptide is commonly supplied as the acetate salt with the molecular formula C221H366N72O67S and a molecular weight of approximately 5,135.8 g/mol. It is identified by CAS number 218949-48-5.

Tesamorelin Research Overview

Tesamorelin has attracted sustained scientific interest as a well-characterized GHRH analog with an extensive research history spanning over two decades. It is the only growth hormone-releasing hormone (GHRH) analog ever approved by the FDA for human use, receiving approval in 2010 under the brand name Egrifta for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.

Research interest in Tesamorelin centers on its ability to bind the GHRH receptor (GHRH-R) on somatotroph cells of the anterior pituitary, activating intracellular signaling cascades that lead to growth hormone synthesis and secretion. Unlike direct administration of exogenous growth hormone, Tesamorelin stimulates the pituitary gland to produce and secrete endogenous GH in a physiological, pulsatile pattern rather than flooding the body with exogenous human growth hormone. This mode of action preserves the natural pulsatile release of GH and remains subject to the body’s own negative feedback mechanisms, primarily through somatostatin. Consequently, Tesamorelin has generated significant interest as a research tool for investigating GHRH receptor pharmacology, somatotroph function, the hypothalamic-pituitary-somatotroph axis, and metabolic regulation.

When researchers choose to buy Tesamorelin in Switzerland for laboratory studies, they gain access to a compound that may help elucidate mechanisms of GHRH receptor signaling, cAMP-mediated transcription, and growth hormone regulation at the molecular level.

How Does Tesamorelin Work?

Tesamorelin exerts its biological effects through binding to the growth hormone-releasing hormone receptor (GHRH-R), a class B G-protein coupled receptor (GPCR) predominantly expressed on the surface of somatotroph cells in the anterior pituitary gland. The peptide’s mechanism involves several well-characterized steps.

GHRH Receptor Binding and Activation

Tesamorelin acts as a selective agonist at the GHRH receptor. In vitro, tesamorelin binds and stimulates human GHRH receptors with similar potency as the endogenous GHRH. This binding induces a conformational change in the receptor, which in turn activates its associated heterotrimeric G-protein. The G-protein primarily associated with the GHRH-R is the stimulatory G-protein, Gs.

cAMP/PKA Signaling Pathway

Upon activation of the Gs protein, a cascade of intracellular signaling events is initiated. The primary and most well-elucidated pathway is the cyclic adenosine monophosphate (cAMP) / Protein Kinase A (PKA) pathway. The activation of the Gs alpha subunit by the tesamorelin-bound GHRH-R leads to the stimulation of adenylyl cyclase, which catalyzes the conversion of ATP to cyclic AMP (cAMP). The subsequent increase in intracellular cAMP levels activates Protein Kinase A (PKA).

Activated PKA then phosphorylates various downstream targets, including the transcription factor cAMP response element-binding protein (CREB). Phosphorylated CREB translocates to the nucleus and binds to cAMP response elements (CRE) in the promoter region of the growth hormone gene, thereby enhancing its transcription. This leads to an increased synthesis of GH mRNA and, consequently, growth hormone.

Pulsatile GH Secretion and Physiological Effects

Stimulation from Tesamorelin results in a significant, yet pulsatile, increase in circulating GH levels. The released GH then acts systemically, binding to cellular receptors located on chondrocytes, myocytes, osteoblasts, hepatocytes, and adipocytes, resulting in a host of pharmacodynamic effects. Some, but not all, of these effects are primarily mediated by IGF-1 produced in the liver and in peripheral tissues.

Researchers who buy Tesamorelin in Switzerland for research purposes can investigate these mechanisms across diverse experimental models of GHRH receptor signaling, somatotroph function, and growth hormone physiology.

Why Is Tesamorelin Studied?

Researchers study Tesamorelin primarily for its potential relevance to GHRH receptor pharmacology, somatotroph function, growth hormone physiology, and metabolic regulation. The peptide’s ability to selectively activate the GHRH receptor and stimulate endogenous GH secretion in a physiological, pulsatile manner makes it a valuable tool for understanding the molecular basis of the hypothalamic-pituitary-somatotroph axis.

Tesamorelin has been extensively studied in the context of metabolic research, particularly for its effects on visceral adipose tissue. In HIV-infected patients with lipodystrophy, Tesamorelin has demonstrated efficacy in reducing visceral adipose tissue (VAT) and improving body composition. Research has also explored its effects on hepatic fat, lean body mass, and IGF-1 levels.

Moreover, researchers study Tesamorelin in the context of cognitive function and neuroprotection. Recent studies have investigated the effects of Tesamorelin on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment. Other areas of investigation include non-alcoholic fatty liver disease (NAFLD), age-related somatopause, and metabolic syndrome.

Researchers who buy Tesamorelin in Switzerland from Core Peptides can incorporate this peptide into their studies on GHRH receptor signaling, somatotroph function, growth hormone physiology, and metabolic research.

Tesamorelin Research Areas

Research Area	Description
GHRH Receptor Pharmacology	Investigating Tesamorelin’s binding affinity and selectivity for the GHRH receptor
Somatotroph Function	Studying Tesamorelin’s effects on GH synthesis and secretion in pituitary cells
cAMP/PKA Signaling	Examining Tesamorelin’s activation of adenylyl cyclase and downstream CREB-mediated transcription
Growth Hormone Physiology	Exploring Tesamorelin’s role in pulsatile GH secretion and the hypothalamic-pituitary-somatotroph axis
Metabolic Research	Investigating Tesamorelin’s effects on visceral adipose tissue, lipid metabolism, and body composition
Hepatic Fat Research	Studying Tesamorelin’s effects on liver fat and NAFLD/NASH models
Cognitive Function	Preclinical research into Tesamorelin’s effects on cognition and brain connectivity
Endocrine Research	Investigating Tesamorelin’s effects on the GH/IGF-1 axis and hormonal regulation

Scientific Research on Tesamorelin

Researchers have conducted extensive scientific studies on Tesamorelin in both in vitro and in vivo settings, deriving evidence from cell cultures, preclinical models, and clinical research. The peptide has an extensive research history spanning over two decades and remains the only FDA-approved GHRH analog.

In Vitro Evidence

In vitro studies using pituitary cell cultures have demonstrated that Tesamorelin binds to the GHRH receptor on somatotroph cells with similar potency to endogenous GHRH. This binding activates Gs-protein-coupled adenylyl cyclase and increases intracellular cAMP concentrations. Research has confirmed that the N-terminal hexenoyl modification does not alter the peptide’s receptor binding profile while significantly enhancing its stability.

Preclinical Animal Studies

In animal models, researchers have investigated Tesamorelin’s effects on growth hormone secretion, pituitary function, and metabolic regulation. The peptide has been studied in various experimental settings, including models of metabolic dysfunction, adipose tissue research, and growth hormone deficiency.

Human Research

Tesamorelin has been extensively studied in human clinical research. The FDA initially approved Tesamorelin (Egrifta) in November 2010 for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. A new formulation (Egrifta WR / Tesamorelin F8) received FDA approval in 2025.

In HIV-associated lipodystrophy, a meta-analysis of four randomized controlled trials (909 patients) demonstrated that Tesamorelin 2mg significantly reduced visceral adipose tissue. Research has also shown that Tesamorelin improves body composition, hepatic fat, lean body mass, and IGF-1 levels in HIV-associated lipodystrophy without serious side effects or perturbation of glucose.

Clinical studies have also investigated Tesamorelin for cognitive function, with a 2026 double-blind placebo-controlled study assessing the effects of Tesamorelin on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment. Additional research has explored its potential in non-alcoholic fatty liver disease (NAFLD).

Nevertheless, researchers should note that Tesamorelin is supplied for laboratory research purposes only. Scientists who buy Tesamorelin in Switzerland should remain aware of these evidence considerations.

Tesamorelin Compared With Related Peptides

Peptide	Relationship to Tesamorelin	Key Differences
Native GHRH (1-44)	Parent compound; Tesamorelin is a modified analog	Native GHRH has rapid DPP-IV degradation (minutes); Tesamorelin has N-terminal hexenoyl modification for enhanced stability (~tripled half-life)
Sermorelin	Both are GHRH analogs	Sermorelin is a 29-amino acid fragment (GHRH 1-29); Tesamorelin is the full 44-amino acid sequence with enhanced stability
CJC-1295	Both are GHRH analogs	CJC-1295 has Drug Affinity Complex for extended half-life; Tesamorelin has N-terminal hexenoyl modification
GHRP-2/Ipamorelin	Both studied for growth hormone research	GHRPs are ghrelin receptor agonists (different mechanism); Tesamorelin is a GHRH receptor agonist
Growth Hormone (GH)	Tesamorelin stimulates endogenous GH secretion	GH is direct exogenous administration; Tesamorelin stimulates natural pulsatile GH release

Research Applications

Researchers utilize Tesamorelin in a variety of laboratory research applications, primarily in the fields of endocrinology, receptor pharmacology, and metabolic research. Key research applications include:

• GHRH Receptor Studies: Investigating Tesamorelin’s binding affinity and selectivity for the GHRH receptor
• Somatotroph Function Research: Studying Tesamorelin’s effects on GH synthesis and secretion in pituitary cells
• cAMP/PKA Signaling Studies: Examining Tesamorelin’s activation of adenylyl cyclase and downstream CREB-mediated transcription
• Growth Hormone Physiology Research: Exploring Tesamorelin’s role in pulsatile GH secretion and the hypothalamic-pituitary-somatotroph axis
• Metabolic Research: Investigating Tesamorelin’s effects on visceral adipose tissue, lipid metabolism, and body composition
• Hepatic Fat Research: Studying Tesamorelin’s effects on liver fat and NAFLD/NASH models
• Cognitive Function Research: Preclinical research into Tesamorelin’s effects on cognition and brain connectivity
• Endocrine Research: Investigating Tesamorelin’s effects on the GH/IGF-1 axis and hormonal regulation

Researchers who buy Tesamorelin in Switzerland can incorporate this peptide into their experimental protocols across these diverse research areas.

Tesamorelin Product Specifications

Specification	Detail
Product Name	Tesamorelin
Amount	5mg / 10mg
Form	Lyophilized powder
Sequence (One-Letter)	trans-3-hexenoyl-YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL-NH2
Sequence (Three-Letter)	trans-3-hexenoyl-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2
Length	44 amino acids
Molecular Formula	C221H366N72O67S
Molecular Weight	Approximately 5,135.8 g/mol (free base)
CAS Number	218949-48-5
N-Terminal Modification	trans-3-hexenoyl (hexenoyl cap)
C-Terminal Modification	Amidation (-NH2)
Half-Life	26-38 minutes
Source	Synthetic (GHRH analog)
Mechanism	GHRH receptor agonist; cAMP/PKA pathway activation; GH secretion stimulation
Research Category	Growth Hormone Peptides
Purity	>99% (HPLC)
Storage	Store desiccated at -20°C, protected from light

How to Evaluate Tesamorelin Quality

When sourcing Tesamorelin for research purposes, researchers should consider several quality indicators. A reliable Tesamorelin peptide supplier should provide:

• Identity Confirmation: Analytical verification that the peptide matches the expected 44-amino acid sequence (trans-3-hexenoyl-YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL-NH2) and molecular weight (approximately 5,135.8 g/mol)
• Purity Analysis: Documentation of purity through methods such as HPLC – research grade typically provides >99% purity
• N-Terminal Hexenoyl Modification Confirmation: Verification of the trans-3-hexenoyl modification, which is critical for the peptide’s stability and resistance to enzymatic degradation
• Batch Information: Clear lot numbers and batch traceability
• Certificate of Analysis (CoA): Documentation of analytical testing results
• Appearance: White to off-white lyophilized powder

Researchers looking to buy Tesamorelin in Switzerland should seek suppliers who provide comprehensive documentation and quality assurance. Core Peptides remains committed to supporting research with properly documented products.

Understanding the Certificate of Analysis

A Certificate of Analysis (CoA) provides analytical data for a specific batch of a research peptide. For Tesamorelin research, a CoA typically includes:

• Identity Confirmation: Mass spectrometry confirming the peptide’s identity
• Purity Assessment: HPLC chromatograms showing the purity of the peptide
• Batch/Lot Information: Unique identifiers for traceability
• Analytical Methods: Description of the testing methods used

Importantly, researchers should understand that a CoA demonstrates the chemical identity and purity of a peptide but does not establish safety, efficacy, therapeutic effectiveness, or suitability for human use. The CoA serves as a quality control document for research purposes only.

Storage and Stability

Proper storage of research peptides is essential for maintaining their integrity and stability. For Tesamorelin, researchers should refer to the product documentation provided with their order for specific storage recommendations.

General best practices for Tesamorelin storage include keeping the lyophilized peptide desiccated, protected from light, and stored at -20°C or below. The N-terminal hexenoyl modification provides enhanced resistance to enzymatic degradation compared to native GHRH. For specific temperature requirements and reconstitution protocols, consult the applicable product documentation or contact Core Peptides for the applicable storage specifications.

Research Considerations

Researchers incorporating Tesamorelin into their studies should be aware of several important considerations:

• Clinical Status: Tesamorelin has been extensively studied in human clinical research and received FDA approval in 2010 for HIV-associated lipodystrophy. However, the peptide is supplied for laboratory research purposes only.
• Experimental Status: Researchers consider Tesamorelin a well-characterized compound, but findings should be interpreted within the context of ongoing research.
• Model Differences: Results from cell cultures and animal models may not translate directly to human outcomes.
• Regulatory Status: Tesamorelin is not FDA-approved for research applications and is intended for laboratory research use only.
• Quality Considerations: Researchers should verify the quality and identity of their Tesamorelin through appropriate analytical methods.
• Mechanistic Context: Tesamorelin’s proposed mechanisms involve GHRH receptor binding, Gs-protein activation, cAMP/PKA signaling, and CREB-mediated transcription. Researchers should consider appropriate experimental approaches to investigate these pathways.
• Stability Enhancement: The N-terminal hexenoyl modification significantly enhances the peptide’s stability compared to native GHRH, which may influence experimental design.
• Half-Life: Tesamorelin has a half-life of approximately 26-38 minutes, which should be considered when designing dosing protocols.

Researchers who buy Tesamorelin in Switzerland should ensure their studies include appropriate controls and interpret findings with scientific rigor.

Frequently Asked Questions About Tesamorelin

What is Tesamorelin?

Tesamorelin is a synthetic 44-amino acid peptide corresponding to the full-length sequence of endogenous GHRH(1-44) with an N-terminal trans-3-hexenoyl modification that enhances stability and resistance to enzymatic degradation.

What is Tesamorelin researched for?

Researchers primarily investigate Tesamorelin for its binding to the GHRH receptor, activation of the cAMP/PKA signaling pathway, stimulation of endogenous growth hormone synthesis and secretion, and its role in somatotroph function, growth hormone physiology, and metabolic regulation.

What is the amino acid sequence of Tesamorelin?

The amino acid sequence of Tesamorelin is trans-3-hexenoyl-YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL-NH2.

What is the molecular weight of Tesamorelin?

The molecular weight of Tesamorelin is approximately 5,135.8 g/mol.

What is the CAS number for Tesamorelin?

The CAS number for Tesamorelin is 218949-48-5.

What is the mechanism of action for Tesamorelin?

Tesamorelin binds to the GHRH receptor on anterior pituitary somatotroph cells, activating Gs-protein-coupled adenylyl cyclase, increasing intracellular cAMP, activating PKA, and promoting CREB-mediated transcription of the growth hormone gene.

How does Tesamorelin differ from native GHRH?

Native GHRH has rapid DPP-IV degradation (minutes); Tesamorelin has an N-terminal trans-3-hexenoyl modification that enhances stability and roughly triples its plasma persistence without altering receptor binding.

Does Tesamorelin preserve natural GH pulsatility?

Yes, unlike direct GH administration, Tesamorelin stimulates the body’s own pituitary gland to produce and secrete GH, preserving the natural pulsatile release pattern.

Is Tesamorelin FDA-approved?

Tesamorelin received FDA approval in 2010 for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. However, it is supplied for laboratory research purposes only.

Can I buy Tesamorelin in Switzerland?

Yes, researchers can buy Tesamorelin in Switzerland from Core Peptides for laboratory research purposes.

What is the primary research category for Tesamorelin?

Tesamorelin belongs to the Growth Hormone Peptides category, with secondary relevance to Cellular Research & Signaling research.

What related peptides are studied alongside Tesamorelin?

Related peptides include native GHRH, Sermorelin, CJC-1295, GHRP-2, Ipamorelin, and Growth Hormone.

What is the purity of Core Peptides’ Tesamorelin?

Core Peptides provides Tesamorelin with a purity of >99% as verified by HPLC analysis.

How should Tesamorelin be stored?

Tesamorelin should be stored lyophilized, desiccated, protected from light, at -20°C or below.

What is the half-life of Tesamorelin?

Tesamorelin has a half-life of approximately 26-38 minutes.

Related Research Peptides

Researchers interested in Tesamorelin may also find the following related peptides relevant to their work:

• Sermorelin – A 29-amino acid GHRH fragment (GHRH 1-29) studied for GHRH receptor research
• CJC-1295 – A GHRH analog with Drug Affinity Complex for extended half-life studies
• GHRP-2 – A ghrelin receptor agonist studied for growth hormone research
• Ipamorelin – A selective ghrelin receptor agonist studied for growth hormone research
• Growth Hormone – The downstream hormone regulated by GHRH signaling

For a comprehensive selection of research peptides in Switzerland, explore the Core Peptides catalog.

Explore Growth Hormone Peptides

Tesamorelin is part of our Growth Hormone Peptides category, which features a range of research peptides investigated for their effects on growth hormone physiology, pituitary function, and metabolic research. Browse our selection to find the right peptides for your laboratory research.

Explore Related Research Categories

Researchers may also find the following related categories relevant to Tesamorelin research:

• Cellular Research & Signaling – Peptides studied for receptor signaling and GPCR pathways
• Anti-Aging & Longevity – Peptides investigated for age-related endocrine and metabolic research
• Healing & Regeneration Peptides – Peptides investigated for tissue repair and regeneration

Further Research

Researchers interested in learning more about Tesamorelin and related peptides should consult the primary scientific literature. Key areas of investigation include GHRH receptor biology, cAMP/PKA signaling, somatotroph function, growth hormone physiology, and metabolic regulation. The PubMed database is an excellent resource for accessing peer-reviewed research articles on these topics.

Research Disclaimer

Core Peptides supplies Tesamorelin as a research peptide for laboratory research purposes only. It is not approved for human consumption, therapeutic use, or medical treatment. All information provided is for educational and scientific reference purposes only and does not constitute medical advice. Researchers are responsible for ensuring compliance with all applicable laws and regulations governing the use of research peptides in their jurisdiction, including Switzerland.